Team:ATOMS-Turkiye

From 2014.igem.org

(Difference between revisions)
Line 88: Line 88:
<div class="withImage">
<div class="withImage">
<h2>Project Abstract</h2>
<h2>Project Abstract</h2>
-
<p><a href="#"></a>Tissue hypoxia, or ischemia, is the condition that describes the poor conveyance of oxygen and other vital products to body tissues and organs which consequently results tissue death. Up to now, the number one cause of death worldwide is caused by ischemia and related conditions such as heart attack or stroke. It is needed to regard the big picture of the condition in order to solve the problem. In our project, our will is to build two different devices, which work synergistically, to fix these two distinct situations. We decided to use ‘’hypoxia inducible systems” and ‘’reactive oxygen species (ROS) sensitive gene fragments’’. These two receptors will hopefully regulate the release of clot dissolving factors and antioxidant peptides synthesized by our engineered vessel cells. We hope to bring encouraging results in vitro to pave the way of this promising system into the lifesaving remedy method.</p>
+
<p><a href="#"></a>The condition which results in tissue death due to the poor conveyance of oxygen and other products vital for tissue cells and organs is described as tissue hypoxia or ischemia. Currently, ischemia and other related conditions such as heart attacks and strokes take the lead for being the number one cause of death worldwide. Moreover, the current treatment of ischemic attacks can intensify the damage in the tissue caused by hypoxia which is known as oxidative stress. This is due to the high oxygen concentration of the restored blood supply. Without a doubt, we need to view the bigger picture of the condition in order to solve this problem. In our project, we desire to build two different devices which work synergistically and fix these these two distinct situations, hypoxia and oxidative stress. Hence, we have decided to use "hypoxia inducible systems" and "reactive oxygen species (ROS) sensitive gene fragments". These two receptors will regulate the release of clot dissolving factors and antioxidant peptides synthesized by our engineered vessel cells. Through attaining encouraging in-vitro results, we aim to pave the way of this promising system into a lifesaving remedy.</p>
</div>
</div>
Line 95: Line 95:
         <ul>
         <ul>
             <li class="one">
             <li class="one">
-
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="tit">Modeling</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="lnk"><span><strong>This year, we have carried out a mathematical modeling to understand how our promoter system would react against hypoxia to be able to treat heart problems. To learn more, click here</strong></span></a>
+
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="tit">Modeling</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="lnk"><span><strong>This year, we have carried out a mathematical modeling to understand how our promoter system would react against hypoxia to be able to treat heart problems. To learn more, click here.</strong></span></a>
-
                     <img src="https://static.igem.org/mediawiki/2014/0/03/ATOMS-Modelling1.png" alt="This is the place of Modeling results" width="210" height="220"><b>This is the place of Modeling results...</b>
+
                     <img src="https://static.igem.org/mediawiki/2014/thumb/6/6f/ATOMS-main-modeling.png/685px-ATOMS-main-modeling.png" alt="This year, we have carried out ..." width="210" height="220"><b>This year, we have carried out ....</b>
                 </div>
                 </div>
Line 104: Line 104:
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/BioBricks#main" class="tit">BioBricks</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/BioBricks#main" class="lnk"><span><strong>Our team proposes seven new eukaryotic cell parts to the Registry consisting of three promoters and four different enzymes with various capabilities. To get detailed information, proceed here.</strong></span></a>
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/BioBricks#main" class="tit">BioBricks</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/BioBricks#main" class="lnk"><span><strong>Our team proposes seven new eukaryotic cell parts to the Registry consisting of three promoters and four different enzymes with various capabilities. To get detailed information, proceed here.</strong></span></a>
-
                     <img src="https://static.igem.org/mediawiki/2014/1/16/Atoms_turkiye_main_page_diagram.jpg" alt="This is a comprehensive wiev of project" width="210" height="220"><b>This is a comprehensive wiev of project...</b>
+
                     <img src="https://static.igem.org/mediawiki/2014/1/16/Atoms_turkiye_main_page_diagram.jpg" alt="Our team proposes seven new eukaryotic cell parts ..." width="210" height="220"><b>Our team proposes seven new eukaryotic cell parts ...</b>
                 </div>
                 </div>
Line 111: Line 111:
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Achievements" class="tit">Achievements</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Achievements" class="lnk"><span><strong>It was a long study session; but it's worth. We accomplished several of our tasks to establish a fully beneficial treatment for heart attacks. To check out what we achieve, click here.</strong></span></a>
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Achievements" class="tit">Achievements</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Achievements" class="lnk"><span><strong>It was a long study session; but it's worth. We accomplished several of our tasks to establish a fully beneficial treatment for heart attacks. To check out what we achieve, click here.</strong></span></a>
-
                     <img src="https://static.igem.org/mediawiki/2014/e/e5/Atoms_turkiye_biobricks_odd_small.jpg" alt="Mechanism of ODD..." width="210" height="220"><b>It was a long study session; but...</b>
+
                     <img src="https://static.igem.org/mediawiki/2014/thumb/8/8a/ATOMS-main-Checklist.jpg/800px-ATOMS-main-Checklist.jpg" alt="Mechanism of ODD..." width="210" height="220"><b>It was a long study session; but...</b>
                 </div>
                 </div>

Revision as of 17:55, 17 October 2014

Project Abstract

The condition which results in tissue death due to the poor conveyance of oxygen and other products vital for tissue cells and organs is described as tissue hypoxia or ischemia. Currently, ischemia and other related conditions such as heart attacks and strokes take the lead for being the number one cause of death worldwide. Moreover, the current treatment of ischemic attacks can intensify the damage in the tissue caused by hypoxia which is known as oxidative stress. This is due to the high oxygen concentration of the restored blood supply. Without a doubt, we need to view the bigger picture of the condition in order to solve this problem. In our project, we desire to build two different devices which work synergistically and fix these these two distinct situations, hypoxia and oxidative stress. Hence, we have decided to use "hypoxia inducible systems" and "reactive oxygen species (ROS) sensitive gene fragments". These two receptors will regulate the release of clot dissolving factors and antioxidant peptides synthesized by our engineered vessel cells. Through attaining encouraging in-vitro results, we aim to pave the way of this promising system into a lifesaving remedy.

Retrieved from "http://2014.igem.org/Team:ATOMS-Turkiye"